Member Info for Jace86

In there is mention of the sensitivity specificity. For us, not much else matters I guess other than those numbers and when the application is granted.

Vincent - Use Google patent finder.

Derives from WO2017068330A1. Application was PCT/GB2016/053203. (In the prospectus the 3 is missing off the end).

Pay attention to this one...

Hoping soon this can be announced properly and get things moving. Or maybe can be done under "patent pending"?

We was talking about this in telegram group last night. Not sure if you are in or not.

It looks unclear. If they have and did so at the top, great.

But the piece makes assumptions and not assertions.

I believe we should be told if the PUT exercise was to sell. Going back to an old debate on what the PUT means for us as opposed to what a PUT traditionally means.

Not just Bio-Techne either.

Corepath, Bosch, Sinopharm to name some others.

We've had Fairjourney do work for us too.

To claim this is a scam or even a lifestyle company when it's clear the wages aren't reflective of that is garbage.

If you want to blame the share price action on anyone, ask, how much of a companies shares can a market maker hold without informing a market.

This end of the market is filled with entities that don't care about you, the investor. The only way to change that is to squeeze them. So when trials are done marker(s) applied for, product launch, this will move fast. They'll have to let go of what stock they are holding.

People chasing dog muck elsewhere. The majority of people at this end of the market belong in a bookmakers.

30p would be far too cheap. Stop thinking in pennies.

OAPK20 - Or not just best in market but well networked...

Think of the involvement here.

Really hard to put a number on that...

Around 30p?

But wouldn't they be selling at a loss?

Joe, look at tempest therapeutics today...

The only ones losing their shizzle are the ones who post all sorts of emotional reactions to the price each day and then opt to focus on a side show

Initially thought US could be anything between $250 and $450.

Cheaper in China and Europe.

Everyone is applying knowledge from a regular IPO to SPACS. They don't work like a regular IPO.

Gambler - the SP is really dependent on players at this end of the market managing to hold for more than a few hours.

We are caught in a low mcap web at the moment where certain groups won't invest unless the mcap is higher and there is a a commencement of testing.

I'm not worried about the SP unless someone comes along and tries to take this off the market on the cheap.

A validation and market launch would see this go much further north. It's then how much of the market can we appeal to and capture. It's big. And we don't even need to capture a big piece of it. A small percentage in each territory is worth an mcap of billions.

Gambler - it works.

Look at some recent videos and read between the lines of what is being said.

Specifically research phase to commercial phase and then after that.

We pretty much only need protocols completing and a small retrospective trial.

Worth a read.

https://www.ft.com/content/466e8009-a7e7-41f4-8ec7-8e101fbca884

It would be nice to have a script for all conferences they've been to and presentation material.

These could be shared on various socials.

Wouldn't be a bad thing if E3 had a buyer lined up for their shares... I wouldn't be averse to an institution wanting an easy few million shares if they are strong holders.

Remember, it is not a drug trial.

It's a simple SOP and retrospective study.

It's a medical device.